Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH Abstract Gangliogliomas are generally benign neuroepithelial tumors composed of dysplastic neuronal and neoplastic glial elements. We screened 61 gangliogliomas [World Health Organization (WHO) grade I] for genomic alterations by chromosomal and array-based comparative genomic hybridization (CGH). Aberrations were detected in 66% of gangliogliomas (mean +/-SEM = 2.5 +/-0.5 alterations/tumor). Frequent gains were on chromosomes 7 (21%), 5 (16%), 8 (13%), 12 (12%); frequent losses on 22q (16%), 9 (10%), 10 (8%). Recurrent partial imbalances comprised the minimal overlapping regions dim(10)(q25) and enh(12)(q13.3-q14.1). Unsupervised cluster analysis of genomic profiles detected two major subgroups (group I: complete gain of 7 and additional gains of 5, 8 or 12; group II: no major recurring imbalances, mainly losses). A comparison with low-grade gliomas (astrocytomas WHO grade II) showed chromosome 5 gain to be significantly more frequent in gangliogliomas. Interphase fluorescence in situ hybridization (FISH) identified the aberrations to be contained in a subpopulation of glial but not in neuronal cells. Two gangliogliomas and their anaplastic recurrences (WHO grade III) were analyzed. Losses of CDKN2A/B and DMBT1 or a gain/amplification of CDK4 found in the anaplastic tumors were already present in the respective gangliogliomas by array CGH and interphase FISH. In summary, genomic profiling in a large series of gangliogliomas could distinguish genetic subgroups even in this low-grade tumor. 
and glial components by staining for GFAP in gangliogliomas (6, 8) . In addition, approximately 75% of tumors were found to exhibit immunoreactivity for the stem cell epitope CD34 (7) . Clinically, gangliogliomas are the most common tumors associated with chronic temporal lobe epilepsy (6, 8) .
Very little is known about the molecular pathogenesis of gangliogliomas. Few gangliogliomas have been analyzed cytogenetically indicating involvement of chromosome 7
in numerical or structural aberrations as the only alteration detected in more than two cases (18, 19, 23, 30, 40) . Gain on chromosome 7 was also found recurrently by chromosomal comparative genomic hybridization (CGH) analysis of less than 10 cases performed to date (31, 38, 46) . Certain genes with relevance in other brain tumor entities (e.g. TP53, EGFR, PTEN) were not shown to play a substantial role in the pathogenesis of gangliogliomas (11, 39). There was also no evidence for mutations in genes of the reelin pathway (e.g. CDK5, DCX, CDK5R1, DAB1), a major signal transduction cascade in neuronal development and cellular migration, in these tumors (4, 22) . However, gangliogliomas did show lower mRNA expression of these genes compared to normal central nervous system tissue controls (4, 22) .
A number of sequence polymorphisms in the TSC2 gene, a member of the PI3K signaling pathway, were found to be significantly more frequent in gangliogliomas than in constitutional DNA from normal individuals suggesting a role for these sequence alterations in the molecular pathogenesis of these tumors (5) .
To date, no particular genetic alteration has emerged from these studies to be consistently and typically associated with gangliogliomas. Thus, it was the aim of our study to do a genome-wide screen for genomic aberrations in a large series of 61 gangliogliomas by chromosomal (10, 20) and array-based (32, 37) comparative genomic hybridization (CGH).
An unsupervised cluster analysis of the results was performed to investigate whether gangliogliomas could be subclassified on the basis of their genomic profiles. Since the glial cells in gangliogliomas are highly similar to the cells in diffuse astrocytomas histopathologically, the imbalances in gangliogliomas were compared with those in astrocytomas of WHO grade II. To address the question which of the components carried the aberrations found by array-CGH, interphase fluorescence in situ hybridization (FISH) to tumor tissue sections was performed with a separate evaluation of glial and neuronal cells.
Finally, two primary gangliogliomas and their anaplastic recurrences were analyzed by array-CGH and interphase-FISH to identify genetic aberrations correlated with tumor recurrence and set the stage for individualizing therapeutic strategies used for gangliogliomas.
MATERIALS AND METHODS
Tumor samples. CGH analyses were performed on sporadic gangliogliomas from 61 patients (27 female, 34 male; mean age at operation: 27.9 years; Table 1 ). In the 51 patients with long standing epilepsy, presurgical evaluation had been performed before operation within the epilepsy surgery program of the Department of Neurosurgery, Rheinische
Friedrich-Wilhelms-University, Bonn (9). Informed, written consent was obtained from all patients with respect to the use of ganglioglioma tissue for additional studies. As reference DNA for CGH analyses, DNA was extracted from peripheral blood lymphocytes of normal individuals according to standard procedures (36) .
Chromosomal comparative genomic hybridization (CGH). Metaphase spreads
were prepared from stimulated peripheral blood lymphocytes obtained from a healthy male 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Array-based CGH. Twenty gangliogliomas and two anaplastic gangliogliomas, for which high molecular weight DNA could be extracted from frozen tumor samples, were analyzed by array-CGH using genomic DNA microarrays with more than 6000 large insert clones (6k array, 8 tumors), or more than 8000 large insert clones (8k array, 12 tumors). Both arrays contained the Sanger Centre 1Mb clone set covering the genome at an average resolution of ~1Mb (13). On the 6k array, there were 3000 additional gene-and regionspecific RCPI (RZPD, Berlin, Germany) and CalTech (Invitrogen, Karlsruhe, Germany) BAC clones, reaching an average resolution of 0.5Mb (48) . The 8k array contained 2000 additional clones providing tiling-path resolution of the large GC and gene rich regions on chromosomes 1, 19 and 22. Array assembly, hybridization and analysis were essentially performed as described previously (12, 48), with minor modifications. Hybridization of 6k arrays was performed as "dye-swap". 8k arrays were hybridized with Cy3-labeled tumor DNA and Cy5-labeled reference DNA. Reference DNA pools were generated from 10 healthy women and from 10 healthy men. Hybridizations of all gangliogliomas were sex matched. Array-CGH data was processed using the ChipYard framework (URL:
http://www.dkfz.de/genetics/ChipYard/); for tumor aberrations in cell subpopulations, the integrated GLAD-algorithm (16) was used. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (29) were processed by dedicated software implemented in the Perl scripting language using complex Regular Expression based parsing algorithms (1) . Data matrices were generated, containing the imbalance status ("1" = gain, "-1" = loss, "2" = high level gain) for each of 862 chromosomal bands. From this data matrix, the frequency of occurrence of gains and losses for each interval was determined and histograms were generated. For evaluation of divergent imbalance patterns, unsupervised cluster analyses were performed on a reduced density matrix (86 intervals) using the Bioconductor "Heatplus" package Recurrent partial losses and gains were found on chromosomes 10 (4 cases) and 12 (2 cases) ( Figure 2 ). These were losses of 10q22-q26 and 10q25-q26 detected by CGH, as well as of 10q21. The genomic profile allows a separation into two ganglioglioma subgroups.
RESULTS

Genomic imbalances detected by chromosomal or array-CGH.
By unsupervised cluster analysis of gangliogliomas with CGH imbalances, a separation of cases into two major subgroups is apparent ( Comparison between the genomic aberration pattern of gangliogliomas and diffuse astrocytomas. Genomic imbalances in gangliogliomas and 19 diffuse astrocytomas of WHO grade II, which were reported by us previously (42, 43) , were compared (Figure 3 B). While the majority of gains and losses in gangliogliomas involved whole chromosomes, most imbalances in diffuse astrocytomas involved only parts of chromosomes. The most striking difference was gain on chromosome 5, which was found significantly more frequently in gangliogliomas than in diffuse astrocytomas (p = 0.05).
Unsupervised cluster analysis of both tumor entities shows that only one diffuse To investigate which tumor cells carried these losses, we used clones from chromosomes 9
and 22 as probes for interphase-FISH to sections from this tumor. One signal, i.e. a deletion,
for BAC RP11-392G7 (9q22.32) was detected in 52% of glial cells, whereas no deletion was imbalances except for losses on 9 and 22q, which are not exclusive to group II. Interestingly, unsupervised clustering of array CGH data also allowed the molecular subclassification of medulloblastomas into two clusters (28), corroborating our data that genomic profiling can distinguish genetic subgroups within the same brain tumor entity. Intriguingly, this is not only the case for highly malignant CNS tumors, i.e. medulloblastomas, but also for the benign gangliogliomas. and promotes neurite outgrowth (14) . In addition, there is evidence that members of the L1 One of the aims of genomic profiling is to set the stage for an individualized medicine based on the identification of tumors, which will have a different biological behavior than expected from histopathological evaluation. In our series, we had the chance to investigate two gangliogliomas (WHO grade I), for which the rare event of tumor recurrence and malignant progression to anaplastic ganglioglioma (WHO grade III) was observed. By array-CGH analysis, the anaplastic recurrences showed genetic aberrations commonly associated with malignant gliomas, including amplifications of the oncogenes PDGFRA and CDK4 or pronounced losses of the tumor suppressor genes CDKN2A/B and DMBT1 (33) . In the array CGH profiles of the primary gangliogliomas, the CDK4 amplification was detectable as a distinct CDK4 gain in one tumor and the clones containing the CDKN2A/B and DMBT1 genes both showed signal ratios indicating a slight loss in the other case. These aberrations, i.e.
Array-CGH and interphase-FISH results in two gangliogliomas
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